Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Investigative Dermatology

• Publication date

  1998-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1046/J.1523-1747.1998.00414.XPMID 9856847
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of nerve growth factor (NGF) and other fibroblast-derived growth factors on immature human mast cells (HMC-1).

  1998cited by this paper
• Mastocytosis.

  1997cited by this paper
• Mechanisms of constitutive activation of c-kit receptor tyrosine kinase.

  1997cited by this paper
• c-kit mutation in a population of patients with mastocytosis.

  1997cited by this paper
• Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1.

  1996cited by this paper
• Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo

  1996cited by this paper
• Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm

  1996cited by this paper
• Trisomies 9 and 8 detected by fluorescence in situ hybridization in patients with systemic mastocytosis.

  1996cited by this paper
• A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells.

  1996cited by this paper
• Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3.

  1995cited by this paper
• Mast cells in the cytokine network: the what, where from and what for

  1995cited by this paper
• Clinical advances in mastocytosis

  1995cited by this paper
• Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.

  1995cited by this paper
• Expression of stem cell factor in cutaneous mastocytosis

  1995cited by this paper
• Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines.

  1995cited by this paper
• Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation.

  1994cited by this paper
• Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation

  1994cited by this paper
• Urticaria Pigmentosa: A Review of 67 Pediatric Cases

  1994cited by this paper
• Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.

  1993cited by this paper
• Pigmentation and Proliferation of Human Melanocytes and the Effects of Melanocyte‐Stimulating Hormone and Ultraviolet B Light a

  1993cited by this paper
• Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis.

  1993cited by this paper
• Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture.

  1992cited by this paper
• c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas.

  1992cited by this paper
• Classification and diagnosis of mastocytosis: current status.

  1991cited by this paper
• Classification and diagnosis of mastocytosis: current status.

  1991cited by this paper
• Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells.

  1991cited by this paper
• Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles.

  1990cited by this paper
• Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms.

  1990cited by this paper
• Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver--conditioned medium.

  1990cited by this paper
• Analysis of DNA sequences in forty-year-old paraffin-embedded thin-tissue sections: a bridge between molecular biology and classical histology.

  1988cited by this paper
• Primary structure of c‐kit: relationship with the CSF‐1/PDGF receptor kinase family–oncogenic activation of v‐kit involves deletion of extracellular domain and C terminus.

  1988cited by this paper
• Systemic Mast Cell Disease: ANALYSIS OF 58 CASES AND LITERATURE REVIEW

  1988cited by this paper
• Establishment of an immature mast cell line from a patient with mast cell leukemia.

  1988cited by this paper
• Bone marrow findings in adult patients with urticaria pigmentosa.

  1988cited by this paper
• The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus

  1988cited by this paper
• Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.

  1987cited by this paper
• A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors.

  1985cited by this paper
• Urticaria pigmentosa: clinical picture and response to oral disodium cromoglycate

  1981cited by this paper
• Mastocytosis and the Mast Cell

  1967cited by this paper

• Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers

  2024cites this paper
• Therapeutic modulation of KIT ligand in melanocytic disorders with implications for mast cell diseases

  2024cites this paper
• Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management

  2023cites this paper
• Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations

  2022cites this paper
• Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis

  2022cites this paper
• PATHOGENIC AND DIAGNOSTIC RELEVANCE OF KIT IN PRIMARY MAST CELL ACTIVATION DISORDERS.

  2021cites this paper
• Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management

  2021cites this paper
• The Role of Avapritinib for the Treatment of Systemic Mastocytosis

  2021cites this paper
• Precision Medicine in Hymenoptera Venom Allergy: Diagnostics, Biomarkers, and Therapy of Different Endotypes and Phenotypes

  2020cites this paper
• KIT and Other Mutations in Mastocytosis

  2019cites this paper
• Comparison of lesional skin c‐KIT mutations with clinical phenotype in patients with mastocytosis

  2018cites this paper
• Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management

  2018cites this paper
• Kit Mutations: New Insights and Diagnostic Value.

  2018cites this paper
• Mast cell disorders: From infancy to maturity

  2018cites this paper
• Targeted Treatment Options in Mastocytosis

  2017cites this paper
• Systemic mastocytosis with KIT V560G mutation presenting as recurrent episodes of vascular collapse: response to disodium cromoglycate and disease outcome

  2017cites this paper
• Transgenerational transmission of systemic mast cell activation disease-genetic and epigenetic features.

  2016cites this paper
• CME Information

  2016cites this paper
• Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells

  2016cites this paper
• Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management

  2016cites this paper
• Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells

  2016cites this paper
• Cutaneous form of maculopapular mastocytosis in a foal.

  2016cites this paper
• Update on Mastocytosis (Part 1): Pathophysiology, Clinical Features, and Diagnosis.

  2016cites this paper
• Update on Mastocytosis (Part 1): Pathophysiology, Clinical Features, and Diagnosis.

  2016cites this paper
• Pediatric dermatohistopathology – histopathology of skin diseases in newborns and infants

  2015cites this paper
• Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder

  2015cites this paper
• Pädiatrische Dermatohistopathologie – Histologie von Dermatosen im Neugeborenen‐ und Säuglingsalter

  2015cites this paper
• CME Information: Systemic mastocytosis in adults: 2015 update on diagnosis, risk-stratification, and management

  2015cites this paper
• Paediatric mastocytosis: a systematic review of 1747 cases

  2015cites this paper
• Review papers The role of KIT gene mutations in pathogenesis of pediatric mastocytosis

  2015cites this paper
• The Expression of Melanoma Inhibitory Activity on Mast Cells in Child Patients with Cutaneous Mastocytosis

  2014cites this paper
• Molecular defects in mastocytosis: KIT and beyond KIT.

  2014cites this paper
• Telangiectasia macularis eruptiva perstans with congenital onset in a 5-year-old girl

  2014cites this paper
• Identification of KIT activating mutations in paediatric solitary mastocytoma

  2014cites this paper
• Anomalies moléculaires au cours des mastocytoses : conséquences pronostiques et thérapeutiques

  2014cites this paper
• The Overexpression of KIT Proto-Oncogene in Acute Leukemic Cells Is Not Necessarily Caused by the Gene Mutation

  2014cites this paper
• Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms.

  2014cites this paper
• KIT D816V Mutation-Positive Cell Fractions in Lesional Skin Biopsies from Adults with Systemic Mastocytosis

  2013cites this paper
• Anesthetic considerations in pediatric mastocytosis: a review

  2013cites this paper
• hematologic malignancies After chronic myelogenous leukemia: tyrosine kinase inhibitors in other

  2013cites this paper
• CME Information

  2013cites this paper
• Spanish Network on Mastocytosis (REMA) in a series of 113 patients lineages in systemic mast cell disorders: a prospective study of the KIT mutation in mast cells and other bone marrow hematopoietic cell

  2013cites this paper
• Acute myeloid leukemia: 2013 update on risk‐stratification and management

  2013cites this paper
• Refractory cutaneous angiosarcoma successfully treated with sunitinib

  2013cites this paper
• CD1a‐positive familial cutaneous mastocytosis without germ‐line or somatic mutations in c‐kit

  2013cites this paper
• Primary Mast Cell Disorders in Children

  2013cites this paper
• Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level

  2012cites this paper
• Systemic mastocytosis: disease overview, pathogenesis, and treatment.

  2012cites this paper
• Diagnosis, progression patterns and prognostication in mastocytosis

  2012cites this paper
• Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics

  2012cites this paper
• New insights into the pathogenesis, diagnosis, and management of mastocytosis.

  2012cites this paper
• Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management

  2012cites this paper
• Serotonin and its 5-HT1 receptor in human mastocytosis

  2012cites this paper
• Systemic Mastocytosis

  2011cites this paper
• Activation of mitogen activated protein kinase-Erk kinase (MEK) increases T cell immunoglobulin mucin domain-3 (TIM-3) transcription in human T lymphocytes and a human mast cell line.

  2011cites this paper
• Molecular alterations underlying eosinophilic and mast cell malignancies.

  2011cites this paper
• Role of the scf/kit signalling pathway in embryonic stem cells

  2011cites this paper
• Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.

  2011cites this paper
• treatment for hematologic malignancies? Targeting the Ras signaling pathway: a rational, mechanism-based

  2011cites this paper
• Cutaneous Mastocytosis in Twins: Multiple Mastocytomas and Urticaria Pigmentosa in Two Pairs of Monozygotic Twins

  2011cites this paper
• Electrophoresis Mutations in Canine Mast Cell Tumors using Fluorescent Polyacrylamide Gel kit Detection of c

  2011cites this paper
• Continuing medical education program i n American Journal of Hematology

  2011cites this paper
• Persistent Allergic Contact Dermatitis to Plastic Toilet Seats

  2011cites this paper
• Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management

  2011cites this paper
• 40 – Cutaneous infiltrates – non-lymphoid

  2010cites this paper
• 22. Urticaria and Mastocytosis

  2010cites this paper
• Differential Contributions of c-Kit Activating Mutations to Promotion of AML1-ETO Associated Neoplasia

  2010cites this paper
• Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives

  2010cites this paper
• The molecular pathogenesis of myeloproliferative neoplasms

  2010cites this paper
• KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).

  2010cites this paper
• Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.

  2010influential citation
• Mastocytosis in children is associated with mutations in c-KIT.

  2010cites this paper
• Mutations in the fifth immunoglobulin‐like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours

  2010cites this paper
• New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases.

  2010cites this paper
• New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases Short title : Mechanisms of receptor tyrosine kinase activation

  2010cites this paper
• A brownish-red plaque in an adult.

  2009cites this paper
• Tyrosine kinase inhibitors in veterinary medicine.

  2009cites this paper
• Clinical Aspects of Pediatric and Adult Onset Mastocytosis in the Skin

  2009cites this paper
• Generierung eines Mausmodells für Mastozytose durch kontrollierte Ausprägung eines mutierten, konstitutiv aktiven Kit-Rezeptors

  2009cites this paper
• [Mastocytosis--diagnostic criteria and treatment].

  2009cites this paper
• Two Pediatric Cases of Cutaneous Mastocytosis: Searching for a Mutation in the c-kit Gene

  2009cites this paper
• Urticaria and Mastocytosis

  2008cites this paper
• Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases

  2008cites this paper
• Phenotypic and Genotypic Characteristics of Mastocytosis According to the Age of Onset

  2008cites this paper
• Cutaneous Mastocytosis: A Review Focusing on the Pediatric Population

  2008cites this paper
• The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cells

  2008cites this paper
• Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c‐KIT

  2008cites this paper
• Mastocytosis: a rare case of anaphylaxis in paediatric age and literature review.

  2008cites this paper
• Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1

  2008cites this paper
• KIT and Mastocytosis

  2008cites this paper
• Exploring the mast cell enigma: a personal reflection of what remains to be done

  2008cites this paper
• SURGERY Management of Canine Mast Cell Tumors

  2008cites this paper
• Nodular and Diffuse Dermatitis

  2007cites this paper
• Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders.

  2007cites this paper
• Systemic mastocytosis with diffuse cutaneous involvement and haematological disease presenting in utero treated unsuccessfully with vincristine

  2007cites this paper
• Detection of phospho‐STAT5 in mast cells: a reliable phenotypic marker of systemic mast cell disease that reflects constitutive tyrosine kinase activation

  2007cites this paper
• Oncogenes in Myeloproliferative Disorders

  2007cites this paper
• Recent advances in the understanding of mastocytosis: the role of KIT mutations *

  2007cites this paper
• Tryptase detection in bone-marrow blood: a new diagnostic tool in systemic mastocytosis.

  2007cites this paper
• Detection of the c-kit D816V mutation in systemic mastocytosis by allele-specific PCR

  2007cites this paper